U.S. Markets open in 9 hrs 27 mins

Rexahn Pharmaceuticals, Inc. (REXN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.18000.0000 (0.00%)
At close: 4:00PM EDT

Rexahn Pharmaceuticals, Inc.

15245 Shady Grove Road
Suite 455
Rockville, MD 20850
United States
240 268 5300
http://www.rexahn.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees5

Key Executives

NameTitlePayExercisedYear Born
Mr. Douglas J. Swirsky CPA, CFACEO, Pres & Director650.68kN/A1969
Dr. Madhukar H. Trivedi M.D.ConsultantN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. Rexahn Pharmaceuticals, Inc. has collaboration agreements with Zhejiang Haichang Biotechnology Co., Ltd.; and BioSense Global LLC. The company is headquartered in Rockville, Maryland.

Corporate Governance

Rexahn Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.